logo of the EU drugs agency

You are viewing archived content

Please note that this page is a static copy of a previously published web page and is no longer actively maintained.
Be aware that the information contained here may be out-of-date.
For the most recent information, we recommend visiting the main website of the EMCDDA.

Table TDI-109. All clients entering inpatient treatment by primary drug and age at first use, 2011 or most recent year available

Part (vi) All volatile inhalant inpatient clients by country and age at first use

Country<1515-1920-2425-2930-3435-3940-4445+Age knownAge not knownTotal
Belgium01000000101
Bulgaria01010000202
Czech Republic5401000010010
Denmark00000000000
Germany00021100415
Estonia:::::::::::
Ireland110000000101
Greece00000000000
Spain:::::::::::
France:::::::::::
Italy:::::::::::
Cyprus00000000000
Latvia:::::::::::
Lithuania:::::::::::
Luxembourg:::::::::::
Hungary42000000606
Malta:::::::::::
Netherlands00100000123
Austria00000000000
Poland212:1:::::::
Portugal:::::::::::
Romania24001000729
Slovenia:::::::::::
Slovakia192820100050050
Finland01100000202
Sweden100000010101
United Kingdom31::::::::1:
Croatia3000000::2:
Turkey576215411111425147
Norway400000000000
Total93105199422122713237
 

Notes:

: Indicates no data are available.

(1) Data are from 2010.

(2) Data are from 2009. Data presented in the table come from TDI pilot project. Caution should be made when interpreting the data.

(3) Data are from 1st of April 2010 to 31st March 2011.

(4) In Norway the criteria for selecting and grouping cases are main ICD-10 diagnosis codes F11-F16 and F18-F19.

The number of treatment clients in each country is listed in TDI-7

See also Table TDI-11 part(vii), part(viii)

‘General notes for interpreting data'’ on the Explanatory notes and help page.

Source:

Reitox national reports 2011- Table TDI Inpatient Treatment Centres

Page last updated: Friday, 26 April 2013